Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
Previous studies have suggested that the sulphonylurea hypoglycaemic agent gliclazide has specific effects in inhibiting platelet aggregation, and other haemorrheological effects that could be beneficial in preventing diabetic microangiopathy. A double-blind trial of the effect of gliclazide on platelet aggregatory responses was performed in 51 diabetic patients. Insulin- and non-insulin-treated diabetics were assessed during an initial 12-month placebo period, and in a subsequent 24-month active period after randomisation into placebo and gliclazide groups in insulin-treated patients or to glibenclamide and gliclazide groups in non-insulin-treated patients. Platelet-rich plasma was obtained from patients at intervals of at least 6 months during the trial. Circulating platelet aggregates were estimated, platelet aggregation was studied in response to three concentrations of adrenaline, ADP and collagen and thromboxane B2 produced by platelets exposed to collagen was measured. No significant effect of gliclazide was demonstrated on any parameter of platelet function evaluated.
D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D003925:Diabetic Angiopathies / Q000097:blood / Q000517:prevention & control; D004311:Double-Blind Method; D005907:Gliclazide / Q000627:therapeutic use*; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D011897:Random Allocation; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D013453:Sulfonylurea Compounds; D005907:Gliclazide; D005905:Glyburide